Oefelein M G, Smith N D, Grayhack J T, Schaeffer A J, McVary K T
Department of Urology, Northwestern University School of Medicine, Chicago, Illinois, USA.
J Urol. 1997 Oct;158(4):1460-5.
We sought to determine the efficacy of radical retropubic prostatectomy in men with high grade adenocarcinoma of the prostate in a population that had not been screened for prostate specific antigen (PSA).
An inception cohort of 116 men surgically treated for prostate cancer between 1980 and 1991 was created in April 1992 and prospectively followed thereafter. Median followup was 7 years (range 2.2 to 14.6).
The major cause of death in this group of men was prostate cancer, not competing causes. Ten-year disease specific survival was 96% for organ confined (stage pT2c or less) and 78% for unconfined (stage pT3a or greater) disease. Five and 10-year PSA progression-free survival by pathological stage was 83 and 53% for organ confined disease, and 34 and 22% for unconfined disease with negative pelvic lymph node dissection (p = 0.001). Five and 10-year metastasis-free survival was 96% for organ confined disease, and 81 and 62% for unconfined disease (p = 0.011). Men with pelvic lymph node metastasis had 70 and 30% 5 and 10-year metastasis-free survival, and 75 and 55% disease specific survival, respectively. PSA progression-free survival was 33% at 5 years. A significantly decreased risk of PSA progression was observed in men with unconfined carcinoma who received adjuvant external beam radiotherapy.
In men with high grade prostate cancer the major cause of death was prostate cancer, not competing causes. Pathologically confined carcinoma had a significantly decreased rate of metastatic progression. These observations support the bias that early detection in these men at high risk for cause specific death may favorably impact survival.
我们试图确定在未进行前列腺特异性抗原(PSA)筛查的人群中,耻骨后根治性前列腺切除术对前列腺高级别腺癌男性患者的疗效。
1992年4月建立了一个起始队列,该队列包含1980年至1991年间接受前列腺癌手术治疗的116名男性,并对其进行前瞻性随访。中位随访时间为7年(范围2.2至14.6年)。
该组男性的主要死亡原因是前列腺癌,而非其他竞争性病因。器官局限性(pT2c期或更低)疾病的10年疾病特异性生存率为96%,非局限性(pT3a期或更高)疾病为78%。按病理分期,器官局限性疾病的5年和10年无PSA进展生存率分别为83%和53%,盆腔淋巴结清扫阴性的非局限性疾病分别为34%和22%(p = 0.001)。器官局限性疾病的5年和10年无转移生存率为96%,非局限性疾病分别为81%和62%(p = 0.011)。有盆腔淋巴结转移的男性5年和10年无转移生存率分别为70%和30%,疾病特异性生存率分别为75%和55%。5年时的无PSA进展生存率为33%。接受辅助外照射放疗 的非局限性癌男性患者的PSA进展风险显著降低。
在前列腺癌高级别男性患者中,主要死亡原因是前列腺癌,而非其他竞争性病因。病理局限性癌的转移进展率显著降低。这些观察结果支持了这样一种观点,即对这些有特定病因死亡高风险的男性进行早期检测可能对生存产生有利影响。